Combined application of arsenic trioxide and lithium chloride augments viability reduction and apoptosis induction in human rhabdomyosarcoma cell lines

• DOI: 10.1371/journal.pone.0178857
• Publication Date: 2017-06-02T17:52:15Z
• Authors: Sabine B. Schleicher; Julian J. Zaborski; Rosa Riester; Natascha Zenkner; Rupert Handgretinger; Torsten Kluba; Frank Traub; Karen A. Boehme
• Keywords: Science; Q; R; 500; 610; Apoptosis; Enzyme-Linked Immunosorbent Assay; Oxides; Arsenicals; 3. Good health; 03 medical and health sciences; 0302 clinical medicine; Arsenic Trioxide; Cell Line, Tumor; Rhabdomyosarcoma; Medicine; Humans; Lithium Chloride; Research Article

Rhabdomyosarcomas (RMS) are the most prevalent soft tissue sarcomas affecting children and adolescents. Despite intensive treatment consisting of multimodal chemotherapy and surgery RMS patients diagnosed with metastatic disease expect long term survival rates of only 20%. Often multidrug resistance arises upon initial response emphasizing the need for new therapeutic drugs to improve treatment efficiency. Previously, we demonstrated the efficacy of the FDA approved drug arsenic trioxide (ATO) specifically inhibiting viability and clonal growth as well as inducing cell death in human RMS cell lines of different subtypes. In this study, we combined low dose ATO with lithium chloride (LiCl), which is approved as mood stabilizer for the treatment of bipolar disorder, but also inhibits growth and survival of different cancer cell types in pre-clinical research. Indeed, we could show additive effects of LiCl and ATO on viability reduction, decrease of colony formation as well as cell death induction. In the course of this, LiCl induced inhibitory glycogen synthase kinase-3β (GSK-3β) serine 9 phosphorylation, whereas glioma associated oncogene family 1 (GLI1) protein expression was particularly reduced by combined ATO and LiCl treatment in RD and RH-30 cell lines, showing high rates of apoptotic cell death. These results imply that combination of ATO with LiCl or another drug targeting GSK-3 is a promising strategy to enforce the treatment efficiency in resistant and recurrent RMS.